Combination of Rybrevant and Chemotherapy Improves Survival for Some Patients with NSCLC
The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.
Source: curetoday.com